Ind-Swift has received an approval for the proposed scheme of amalgamation of Essix Biosciences and Dashmesh Medicare with itself. The board at its meeting held on November 14, 2011 has granted its in-principle approval for the same.
The amalgamation will be done under section 391 to 394 of the Companies Act, 1956, subject to appropriate statutory and regulatory approvals.
Essix Biosciences and Dashmesh Medicare are both unlisted entities.
Ind-Swift manufactures and markets finished dosage forms, through its different divisions, focusing on the needs of various therapeutic segments. The divisions include Super Speciality, Animal Division, Daignozis, Institutions, Agile, Bio Sciences, Ethical, Health Care, Max Care, Mega care, Neuro and Resurgence.
